scholarly journals Hospitalizations for malignant breast neoplasia in brazilian regions from 2014 to 2018 / Internações por neoplasia maligna da mama nas regiões brasileiras no período de 2014 a 2018

2021 ◽  
Vol 13 ◽  
pp. 711-716
Author(s):  
Yasmim Anayr Costa Ferrari ◽  
Paula Juliana De Oliveira Fontes ◽  
Thandara Rejane Santos Ferreira Andrade ◽  
Ianka Heloisa Alencar Santos ◽  
Anderson Batista Cavalcante
Keyword(s):  
Cáncer De Mama ◽  
Breast Neoplasia ◽  
Malignant Breast

Objetivo: analisar os casos de internação por neoplasia maligna da mama nas regiões brasileiras de 2014 a 2018. Método:  estudo descritivo e quantitativo, realizado através dos dados referentes aos internamentos por neoplasia maligna da mama nas cinco regiões brasileiras disponíveis no Departamento de Informática do Sistema Único de Saúde entre os anos de 2014 a 2018. Resultados: foram notificados 305.086 internamentos por câncer de mama no período de 2014 a 2018. Em 2017 ocorreram o maior número de internações com 65.029 (21,3%) casos, a região Sudeste ocupou o primeiro lugar com 51,1% dos internamentos, houve predominância do sexo feminino (98,9%), cor branca (45,8%) e na faixa etária de 40 a 59 anos (51,3%). Conclusão: os dados encontrados mostram que a conscientização dos profissionais e da população sobre a importância da prevenção e detecção precoce do câncer de mama é um fator essencial para a mudança do panorama no país.

CARCINOMA METAPLÁSICO DE MAMA EM PACIENTE JOVEM: UM RELATO DE CASO

2018 ◽  
Vol 5 (2) ◽  
pp. 41-46
Author(s):  
Matheus Fávero Damasceno ◽  
Alice Assumpção Soares ◽  
Carolina Silva Delgado ◽  
Patricia Fraga Paiva ◽  
Emilio Pereira Assis
Keyword(s):  
Breast Cancer ◽  
Breast Carcinoma ◽  
Literature Review ◽  
Aggressive Behavior ◽  
Biological Behavior ◽  
Cáncer De Mama ◽  
Carcinoma Breast ◽  
Breast Neoplasia ◽  
The World ◽  
Metaplastic Breast Carcinoma

RESUMO CONTEXTUALIZAÇÃO: O câncer de mama é a 2ª neoplasia mais comum entre as mulheres no Brasil e no mundo. Essa doença, relativamente rara antes dos 35 anos possui características altamente heterogêneas, patologia específica e comportamento biológico distinto. Dentre os Subtipos, o Carcinoma Mamário Metaplásico possui uma incidência de apenas 0,2-5% nos casos de câncer de mama. O objetivo desse estudo é relatar, a partir de uma comparação e revisão de literatura, o caso de uma paciente portadora do carcinoma mamário metaplásico, abaixo de 40 anos, pela raridade do tipo histológico e de seu comportamento agressivo. DESCRIÇÃO DA EXPERIÊNCIA: A paciente inicialmente aos 28 anos apresentou o Papiloma Atípico e 2 anos depois desenvolveu o Carcinoma Mamário Metaplásioco, além de múltiplos nódulos metastáticos pulmonares, comum desse subtipo, e hepáticos. CONSIDERAÇÕES FINAIS: Deve-se destacar que é difícil extrair conclusões definitivas quanto ao prognóstico e tratamento destas lesões, uma vez que elas são muito infrequentes na maior parte de série de casos publicados.   Palavras-chave: Carcinoma Mamário Metaplásico, Carcinoma Mamário, Neoplasia Mamária Malígna, Câncer de Mama. ABSTRACT CONTEXT: The breast cancer is the 2nd most common neoplasia among women in Brasil and around the world. This disease, relatively rare before the age of 35 years, has highly heterogeneous characteristics, especific pathology and distinct biological behavior. Among the subtypes, the Metaplastic Breast Carcinoma has an incidence of only 0,2-5% between the breast cancer cases. The purpose of this study is to report, from a comparison and literature review, the case of a patient with Metaplastic Breast Carcinoma, below 40 yers old, due to the rarity of the histological type and its aggressive behavior. EXPERIENCE DESCRIPTION: The patient, inicially 28 years old presented the Atipic Papilloma and 2 years later developed the Metaplastic Breast Carcinoma, in adittion to multiple metastatic pulmonary nodes, common of the type, and hepatic. FINAL CONSIDERATIONS: It should be noted that it is difficult to draw definitive conclusions about the prognosis and treatment of these lesions, since they are very infrequent in most of the series of published cases. Keywords: Metaplastic Breast Carcinoma, Breast Carcinoma, Malign Breast Neoplasia, Breast Cancer.

scholarly journals Cutaneous metastasis as the first manifestation of occult malignant breast neoplasia

2016 ◽  
Vol 91 (5 suppl 1) ◽  
pp. 105-107 ◽  
Author(s):  
Ellem Tatiani de Souza Weimann ◽  
Erica Bruder Botero ◽  
Cinthia Mendes ◽  
Marcel Alex Soares dos Santos ◽  
Rafael Fantelli Stelini ◽  
...  
Keyword(s):  
Cutaneous Metastasis ◽  
Breast Neoplasia ◽  
Malignant Breast

scholarly journals Cosmesis in patients with breast neoplasia submitted to the hypofractionated radiotherapy with of intensity-modulated beam

2018 ◽  
Vol 64 (11) ◽  
pp. 1023-1030 ◽  
Author(s):  
Fabiana Accioli Miranda ◽  
Marina Tamm Lannes Vieira ◽  
Fabio Ynoe de Moraes ◽  
Gustavo Nader Marta ◽  
Heloísa de Andrade Carvalho ◽  
...  
Keyword(s):  
Radical Mastectomy ◽  
Radiotherapy Planning ◽  
Hypofractionated Radiotherapy ◽  
Breast Volume ◽  
Private Institution ◽  
Cosmetic Results ◽  
Breast Neoplasia ◽  
Dosimetric Data ◽  
Malignant Breast ◽  
One Year

SUMMARY OBJECTIVE: To assess the cosmetic satisfaction of patients diagnosed with breast cancer submitted to the hypofractionated radiotherapy with IMRT (hIMRT) technique and its correlation with dosimetric data of the radiotherapy planning. MATERIALS AND METHODS: The retrospective cohort study that assessed women with a diagnosis of malignant breast neoplasia submitted to the conservative treatment or radical mastectomy and treated with hIMRT. In the period between August 2007 to December 2014, in a philanthropic / private institution, 170 records were selected. The cosmetic assessment was carried out by means of the Harvard/RTOG/NSABP scale with one-year minimum range after treatment. The collected dosimetric data were: breast / chest wall volume, volume that received 95% (V95%) and 107% (V107%) of the prescribed dose. RESULTS: The volume of the treated breasts ranged from 169 to 2.103 ml (median = 702; IQR: 535 to 914 ml). Median V95% was 86.7% (54.6-96.6%; IQR: 80.0% to 90.6%); eight (5.7%) patients had V95% higher than 95%. Median V107% was 0% (0%-16.3%; IQR: 0.0% to 0.3% and 13); 9.3% patients had V107% higher than 2%. One hundred and thirty-three (78.2%) patients responded to the cosmetic assessment: 99 (74.4%) considered the cosmetic results excellent. Significant associations between cosmetic assessment and breast volume (p=0.875), V95% (p=0.294) e V107% (p=0.301) were not found. CONCLUSION: The cosmetic results showed favorable when using hIMRT, and the lack of correlation with usual the dosimetric data illustrates the capacity of hIMRT to minimize the heterogeneity of the dose in this endpoint, even in voluminous breasts.

201Tl Scintigraphy in the Evaluation of Palpable and Nonpalpable Breast Lesions: Correlation with Mammography and Ultrasonography

1997 ◽  
Vol 36 (08) ◽  
pp. 282-288 ◽  
Author(s):  
T. Atasever ◽  
A. Özdemir ◽  
I. Öznur ◽  
N. I. Karabacak ◽  
N. Gökçora ◽  
...  
Keyword(s):  
Final Diagnosis ◽  
Lower Sensitivity ◽  
Breast Lesions ◽  
Breast Cancers ◽  
Combined Use ◽  
Malignant Breast ◽  
Malignant Lesions ◽  
Benign Breast Lesions ◽  
Palpable Breast ◽  
Metastatic Sites

Summary Aim: Our goal was to determine the clinical usefulness of TI-201 to identify breast cancer in patients with suspicious breast lesions on clinical examination, and/or abnormal radiologic (mammography and/or ultrasonography) findings. Methods: TI-201 scintigraphy were performed in sixty-eight patients with 70 breast abnormalities (51 palpable, 19 nonpalpable) and compared with mammography and ultrasonography (US). Early (15 min) and late (3 h) images of the breasts were obtained following the injection of 111 MBq (3 mCi) of TI-201. Visual and semiquantitative interpretation was performed. Results: Final diagnosis confirmed 52 malignant breast lesions and 18 benign conditions. TI-201 visualized 47 of 52 (90%) overall malignant lesions. Thirty-eight of 40 (95%) palpable and 9 of 12 (75%) nonpalpable breast cancers were detected by TI-201 scintigraphy. The smallest mass lesion detected by TI-201 measured 1.5x1.0 cm. Eleven breast lesions were interpreted as indeterminate by mammography and/or sonography. TI-201 scintigraphy excluded malignancy in 7 of 8 (88%) patients with benign breast lesions interpreted as indeterminate. Five of the 18 (28%) benign breast lesions showed TI-201 uptake. None of the fibroadenoma and fibrocystic changes accumulated TI-201. TI-201 scintigraphy, mammography and ultrasonography showed 90%, 92%, 85% overall sensitivity and 72%, 56%, 61% overall specificity respectively. Twenty-one of the 28 (75%) axillary nodal metastatic sites were also detected by TI-201. In malignant and benign lesions, early and late lesion/contralateral normal side (L/N) ratios were 1.58 ± 0.38 (mean ± SD) and 1.48 ± 0.32 (p >0.05), 1.87 ± 0.65 and 1.34 ± 0.20 (p<0.05) respectively. The mean early and late L/N ratios of malignant and benign groups did not show statistical difference (p>0.05). Conclusion: Overall, TI-201 scintigraphy was the most specific of the three methods and yielded favourable results in palpable breast cancers, while it showed lower sensitivity in nonpalpable cancers and axillary metastases. Combined use of TI-201 scintigraphy with mammography and US seems to be useful in difficult cases, such as dense breasts and indeterminate breast lesions.

Factors Involved In the Plasminogen Activation System in Human Breast Tumours

1994 ◽  
Vol 71 (05) ◽  
pp. 684-691 ◽  
Author(s):  
László Damjanovich ◽  
Csaba Turzó ◽  
Róza Ádány
Keyword(s):  
Epithelial Cells ◽  
Connective Tissue ◽  
Plasminogen Activators ◽  
Breast Tumour ◽  
Plasminogen Activation ◽  
Malignant Tumours ◽  
Plasminogen Activation System ◽  
Activation System ◽  
Malignant Breast ◽  
Pai 1

SummaryThe plasminogen activation system is a delicately balanced assembly of enzymes which seems to have primary influence on tumour progression. The conversion of plasminogen into serine protease plasmin with fibrinolytic activity depends on the actual balance between plasminogen activators (urokinase type; u-PA and tissue type; t-PA) and their inhibitors (type 1 and 2 plasminogen activator inhibitors; PAI-1 and PAI-2). The purpose of this study was to determine the exact histological localization of all the major factors involved in plasminogen activation, and activation inhibition (plasmin system) in benign and malignant breast tumour samples. Our results show that factors of the plasmin system are present both in benign and malignant tumours. Cancer cells strongly labelled for both u-PA and t-PA, but epithelial cells of fibroadenoma samples were also stained for plasminogen activators at least as intensively as tumour cells in cancerous tissues. In fibroadenomas, all the epithelial cells were labelled for PAM. Staining became sporadic in malignant tumours, cells located at the periphery of tumour cell clusters regularly did not show reaction for PAI-1. In the benign tumour samples the perialveolar connective tissue stroma contained a lot of PAI-1 positive cells, showing characteristics of fibroblasts; but their number was strongly decreased in the stroma of malignant tumours. These findings indicate that the higher level of u-PA antigen, detected in malignant breast tumour samples by biochemical techniques, does not necessarily indicate increased u-PA production by tumour cells but it might be owing to the increased number of cells producing u-PA as well. In malignant tumours PAI-1 seems to be decreased in the frontage of malignant cell invasion; i.e. malignant cells at the host/tumour interface do not express PAI-1 in morphologically detectable quantity and in the peritumoural connective tissue the number of fibroblasts containing PAI-1 is also decreased.

Paciente com câncer: significado da família no seu tratamento

2016 ◽  
Vol 14 (4) ◽  
Author(s):  
Jaene Cristina Lorena ◽  
Renata De Castro Martins
Keyword(s):  
Cáncer De Mama

Objetivo: Conhecer o significado para o paciente com câncer da participação da família no seu tratamento na cidade de Itajubá/MG. Material e métodos: Estudo qualitativo, exploratório, descritivo e transversal, com amostra composta por 20 participantes. Coleta de dados pela técnica metodológica snowball com entrevista semiestruturada. A metodologia de apreciação foi à técnica do Discurso do Sujeito Coletivo fundamentada na Teoria das Representações Sociais e seus pressupostos sociológicos. Resultados: As características de identificação dos participantes revelaram que a maioria era do sexo feminino, entre 61 e 70 anos, com histórico familiar de neoplasia, católicos, aposentados, casados, ensino fundamental incompleto, tipo de família nuclear, mais de quatro filhos, com câncer de mama feminino, tempo de tratamento de 1 a 5 anos, acompanhados durante todo o tratamento pelos filhos. O significado de ter um membro da família participando do seu tratamento para o paciente com câncer foi: é importante, é receber apoio, é uma segurança e é uma felicidade. Conclusão: O paciente com câncer, após diagnóstico da enfermidade, sofre tanto com alterações físicas quanto psicológicas, e diante disso ele necessita de um ponto de segurança para dar início e continuidade no seu tratamento, esse ponto de apoio é a sua família.Palavras-chave: tratamento, família, neoplasias, Enfermagem Oncológica.

Sign in / Sign up

Export Citation Format

Share Document